COMP <GO>
MTVA vs KPRX // EV/EBITDA & P/E VALUATION
MetaVia Inc. (NASDAQ) VS. Kiora Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: MTVA 3
— KPRX 0
■ METRIC PARITY
LAST: $1.19 (+4.39%) • MKT CAP: $7.8M
valuation
—
LAST: $1.76 (-25.42%) • MKT CAP: $7.8M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MTVA VS. KPRX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MTVA | KPRX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 1/9 | +1.00 | MTVA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 32.2 | 17.1 | +15.12 | MTVA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.8M | $7.8M | $52.9K | MTVA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MTVA REV | KPRX REV | MTVA GROSS % | KPRX GROSS % | MTVA FCF | KPRX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$15.7M | -$10.1M |
| FY 2024 | $0 | $16.0M | — | — | -$24.7M | $8.6M |
| FY 2023 | $0 | $0 | — | — | -$10.8M | -$9.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MTVA // BETA —
KPRX // BETA —